ADAMTS4
Basic information
Region (hg38): 1:161184302-161199054
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the ADAMTS4 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 0 | |||||
missense | 56 | 60 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 1 | |||||
Total | 0 | 0 | 56 | 4 | 1 |
Variants in ADAMTS4
This is a list of pathogenic ClinVar variants found in the ADAMTS4 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
1-161191082-T-C | Benign (Aug 05, 2018) | |||
1-161191151-G-C | not specified | Uncertain significance (Aug 28, 2023) | ||
1-161191160-C-A | not specified | Uncertain significance (Aug 17, 2022) | ||
1-161191161-G-A | not specified | Uncertain significance (Feb 14, 2023) | ||
1-161191164-G-A | not specified | Uncertain significance (Oct 05, 2022) | ||
1-161191199-A-G | not specified | Uncertain significance (Nov 13, 2023) | ||
1-161191212-G-A | not specified | Uncertain significance (Mar 27, 2023) | ||
1-161191248-C-T | not specified | Uncertain significance (Dec 18, 2023) | ||
1-161191296-G-C | not specified | Uncertain significance (Mar 01, 2023) | ||
1-161191374-G-A | not specified | Uncertain significance (Jul 25, 2023) | ||
1-161191380-T-C | not specified | Uncertain significance (Dec 09, 2023) | ||
1-161191484-C-T | not specified | Uncertain significance (Dec 20, 2023) | ||
1-161191485-G-A | not specified | Uncertain significance (Mar 29, 2023) | ||
1-161191496-T-C | not specified | Uncertain significance (Feb 28, 2023) | ||
1-161191501-C-A | not specified | Uncertain significance (Feb 28, 2024) | ||
1-161192116-C-T | not specified | Uncertain significance (Mar 20, 2024) | ||
1-161192159-T-C | not specified | Likely benign (Jan 16, 2024) | ||
1-161192161-C-T | not specified | Uncertain significance (Apr 12, 2022) | ||
1-161193214-C-T | not specified | Uncertain significance (Dec 28, 2023) | ||
1-161193293-T-G | not specified | Uncertain significance (Jan 29, 2024) | ||
1-161193298-C-T | not specified | Uncertain significance (Sep 01, 2021) | ||
1-161193374-C-T | not specified | Uncertain significance (Jul 25, 2023) | ||
1-161193666-T-C | not specified | Uncertain significance (Jan 10, 2023) | ||
1-161193687-C-T | not specified | Uncertain significance (Mar 01, 2024) | ||
1-161193691-G-A | not specified | Uncertain significance (May 16, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
ADAMTS4 | protein_coding | protein_coding | ENST00000367996 | 9 | 14749 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00000195 | 0.999 | 125679 | 0 | 69 | 125748 | 0.000274 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.15 | 454 | 529 | 0.859 | 0.0000328 | 5321 |
Missense in Polyphen | 170 | 219.24 | 0.77542 | 2269 | ||
Synonymous | 0.587 | 209 | 220 | 0.950 | 0.0000133 | 1829 |
Loss of Function | 2.85 | 15 | 32.5 | 0.461 | 0.00000173 | 337 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000905 | 0.0000905 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000656 | 0.000653 |
Finnish | 0.000631 | 0.000601 |
European (Non-Finnish) | 0.000268 | 0.000264 |
Middle Eastern | 0.000656 | 0.000653 |
South Asian | 0.000294 | 0.000294 |
Other | 0.000492 | 0.000489 |
dbNSFP
Source:
- Function
- FUNCTION: Cleaves aggrecan, a cartilage proteoglycan, and may be involved in its turnover. May play an important role in the destruction of aggrecan in arthritic diseases. Could also be a critical factor in the exacerbation of neurodegeneration in Alzheimer disease. Cleaves aggrecan at the '392-Glu-|-Ala-393' site.;
- Pathway
- Endochondral Ossification;Post-translational protein modification;Metabolism of proteins;Extracellular matrix organization;Degradation of the extracellular matrix;O-glycosylation of TSR domain-containing proteins;O-linked glycosylation
(Consensus)
Recessive Scores
- pRec
- 0.193
Intolerance Scores
- loftool
- 0.447
- rvis_EVS
- 0.09
- rvis_percentile_EVS
- 60.71
Haploinsufficiency Scores
- pHI
- 0.0847
- hipred
- Y
- hipred_score
- 0.655
- ghis
- 0.398
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.172
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Adamts4
- Phenotype
- renal/urinary system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan);
Gene ontology
- Biological process
- skeletal system development;proteolysis;extracellular matrix disassembly
- Cellular component
- extracellular region;extracellular space;nuclear speck;collagen-containing extracellular matrix
- Molecular function
- protease binding;metalloendopeptidase activity;protein binding;peptidase activity;metallopeptidase activity;metal ion binding